KMT2A and acute leukemia: Pinometostat (EPZ-5676), a DOT1L inhibitor, was tested in children with relapsed or refractory acute leukemias harboring MLL (KMT2A) gene rearrangement (MLL-r) as monotherapy in phase I clinical trial (NCT02141828), but no objective responses were observed in this cohort [157].